Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma

Cancer Immunology, Immunotherapy

Volumn 65, Issue 11, 2016, Pages 1339-1352

  Fenstermaker, Robert A ^a   Ciesielski, Michael J ^a   Qiu, Jingxin ^a   Yang, Nuo ^a,b   Frank, Cheryl L ^a   Lee, Kelvin P ^a   Mechtler, Laszlo R ^a   Belal, Ahmed ^a   Ahluwalia, Manmeet S ^b   Hutson, Alan D ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Apoptosis; Glioma; Immunotherapy; Peptide; Survivin; Vaccine

Indexed keywords

CANCER VACCINE; GAMMA INTERFERON; HLA A2 ANTIGEN; HLA A3 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MESSENGER RNA; SARGRAMOSTIM; SURVIVIN LONG PEPTIDE VACCINE; UNCLASSIFIED DRUG; BIRC5 PROTEIN, HUMAN; HLA-A*02 ANTIGEN; HLA-A*03 ANTIGEN; INHIBITOR OF APOPTOSIS PROTEIN; PEPTIDE; SUBUNIT VACCINE;

ACUTE KIDNEY FAILURE; ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ISOLATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL STUDY; CLINICAL TRIAL; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOGENICITY; INJECTION SITE REACTION; LEUKOPENIA; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; LYMPHOCYTOPENIA; MALE; MIDDLE AGED; MYALGIA; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SEIZURE; SURVIVAL RATE; SURVIVAL TIME; TUMOR CELL; TUMOR LYMPHOCYTE; ACTIVE IMMUNOTHERAPY; BRAIN NEOPLASMS; GENETICS; GLIOMA; IMMUNOLOGY; METABOLISM; MORTALITY; PROCEDURES; RECURRENT DISEASE; SURVIVAL ANALYSIS; T LYMPHOCYTE; TREATMENT OUTCOME;

ADULT; BRAIN NEOPLASMS; CANCER VACCINES; FEMALE; GLIOMA; HLA-A2 ANTIGEN; HLA-A3 ANTIGEN; HUMANS; IMMUNITY, HUMORAL; IMMUNOTHERAPY, ACTIVE; INHIBITOR OF APOPTOSIS PROTEINS; INTERFERON-GAMMA; MALE; MIDDLE AGED; PEPTIDES; RECURRENCE; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TREATMENT OUTCOME; VACCINES, SUBUNIT;

EID: 84984861398     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-016-1890-x     Document Type: Article

References (31)

1. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC (1998) Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396:580–584. doi:10.1038/25141
2. Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917–921
3. Satoh K, Kaneko K, Hirota M, Masamune A, Satoh A, Shimosegawa T (2001) Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer 92:271–278
4. Kajiwara Y, Yamasaki F, Hama S, Yahara K, Yoshioka H, Sugiyama K, Arita K, Kurisu K (2003) Expression of survivin in astrocytic tumors: correlation with malignant grade and prognosis. Cancer 97:1077–1083. doi:10.1002/cncr.11122
5. Verhaak RG, Hoadley KA, Purdom E et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98–110. doi:10.1016/j.ccr.2009.12.020
6. Adida C, Crotty PL, McGrath J, Berrebi D, Diebold J, Altieri DC (1998) Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol 152:43–49
7. Uematsu M, Ohsawa I, Aokage T, Nishimaki K, Matsumoto K, Takahashi H, Asoh S, Teramoto A, Ohta S (2005) Prognostic significance of the immunohistochemical index of survivin in glioma: a comparative study with the MIB-1 index. J Neurooncol 72:231–238. doi:10.1007/s11060-004-2353-3
8. Muller L, Muller-Haegele S, Mitsuhashi M, Gooding W, Okada H, Whiteside TL (2015) Exosomes isolated from plasma of glioma patients enrolled in a vaccination trial reflect antitumor immune activity and might predict survival. Oncoimmunology 4:e1008347. doi:10.1080/2162402X.2015.1008347
9. Andersen MH, Pedersen LO, Capeller B, Brocker EB, Becker JC, thor Straten P (2001) Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res 61:5964–5968
10. Altieri DC (2003) Survivin and apoptosis control. Adv Cancer Res 88:31–52
11. Ciesielski MJ, Ahluwalia MS, Munich SA, Orton M, Barone T, Chanan-Khan A, Fenstermaker RA (2010) Antitumor cytotoxic T-cell response induced by a survivin peptide mimic. Cancer Immunol Immunother 59:1211–1221. doi:10.1007/s00262-010-0845-x
12. Ciesielski MJ, Kozbor D, Castanaro CA, Barone TA, Fenstermaker RA (2008) Therapeutic effect of a T helper cell supported CTL response induced by a survivin peptide vaccine against murine cerebral glioma. Cancer Immunol Immunother 57:1827–1835. doi:10.1007/s00262-008-0510-9
13. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H (1998) The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 188:2357–2368
14. Pardoll DM (1999) Inducing autoimmune disease to treat cancer. Proc Natl Acad Sci USA 96:5340–5342
15. Fenstermaker RA, Ciesielski MJ (2014) Challenges in the development of a survivin vaccine (SurVaxM) for malignant glioma. Expert Rev Vaccines 13:377–385. doi:10.1586/14760584.2014.881255
16. Rohayem J, Diestelkoetter P, Weigle B, Oehmichen A, Schmitz M, Mehlhorn J, Conrad K, Rieber EP (2000) Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. Cancer Res 60:1815–1817
17. Hadrup SR, Gehl J, Sorensen RB, Geertsen PF, Straten PT, Andersen MH (2006) Persistence of survivin specific T cells for seven years in a melanoma patient during complete remission. Cancer Biol Ther 5:480–482
18. Yagihashi A, Asanuma K, Nakamura M, Araya J, Mano Y, Torigoe T, Kobayashi D, Watanabe N (2001) Detection of anti-survivin antibody in gastrointestinal cancer patients. Clin Chem 47:1729–1731
19. Reker S, Meier A, Holten-Andersen L, Svane IM, Becker JC, thor Straten P, Andersen MH (2004) Identification of novel survivin-derived CTL epitopes. Cancer Biol Ther 3:173–179
20. Ciesielski MJ, Apfel L, Barone TA, Castro CA, Weiss TC, Fenstermaker RA (2006) Antitumor effects of a xenogeneic survivin bone marrow derived dendritic cell vaccine against murine GL261 gliomas. Cancer Immunol Immunother 55:1491–1503. doi:10.1007/s00262-006-0138-6
21. Ciesielski MJ, Qiu J, Fenstermaker RA (2014) Survivin as a Cancer Vaccine Target. J Vaccines Vaccin. 5:230. doi:10.4172/2157-7560.1000230
22. Overwijk WW, Restifo NP (2000) Autoimmunity and the immunotherapy of cancer: targeting the “self” to destroy the “other”. Crit Rev Immunol 20:433–450
23. Fangusaro JR, Jiang Y, Holloway MP, Caldas H, Singh V, Boue DR, Hayes J, Altura RA (2005) Survivin, Survivin-2B, and Survivin-deItaEx3 expression in medulloblastoma: biologic markers of tumour morphology and clinical outcome. Br J Cancer 92:359–365. doi:10.1038/sj.bjc.6602317
24. Nakano J, Huang C, Liu D, Masuya D, Yokomise H, Ueno M, Haba R, Sumitomo S (2008) The clinical significance of splice variants and subcellular localisation of survivin in non-small cell lung cancers. Br J Cancer 98:1109–1117. doi:10.1038/sj.bjc.6604253
25. Castro MG, Baker GJ, Lowenstein PR (2014) Blocking immunosuppressive checkpoints for glioma therapy: the more the merrier! Clin Cancer Res 20:5147–5149. doi:10.1158/1078-0432.CCR-14-0820
26. + T-cell responses in the majority of vaccinated cancer patients. Int J Cancer 131:140–149. doi:10.1002/ijc.26365
27. + T cells. Vaccine 26:3987–3997. doi:10.1016/j.vaccine.2008.05.036
28. + T cells. Cancer Res 67:11428–11437. doi:10.1158/0008-5472.CAN-07-1141
29. Shen L, Sundstedt A, Ciesielski M et al (2015) Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models. Cancer Immunol Res 3:136–148. doi:10.1158/2326-6066.CIR-14-0036
30. Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA, Yung WK (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:2572–2578
31. Stupp R, Wong ET, Kanner AA et al (2012) NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer 48:2192–2202. doi:10.1016/j.ejca.2012.04.011